Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Currency in USD
Valuation measures4
| Market cap (intra-day) | 98.61B |
| Enterprise value | 90.47B |
| Trailing P/E | 25.84 |
| Forward P/E | 20.00 |
| PEG ratio (5-yr expected) | 1.45 |
| Price/sales (ttm) | 7.79 |
| Price/book (mrq) | 3.80 |
| Enterprise value/revenue | 6.90 |
| Enterprise value/EBITDA | 19.28 |
Trading information
Stock price history
| Beta (5Y monthly) | 0.14 |
| 52-week change 3 | 11.21% |
| S&P500 52-week change 3 | 21.83% |
| 52-week high 3 | 998.33 |
| 52-week low 3 | 684.81 |
| 50-day moving average 3 | 956.23 |
| 200-day moving average 3 | 855.60 |
Share statistics
| Avg vol (3-month) 3 | 473.07k |
| Avg vol (10-day) 3 | 459.05k |
| Shares outstanding 5 | 107.94M |
| Implied shares outstanding 6 | 109.76M |
| Float 8 | 102.75M |
| % held by insiders 1 | 2.58% |
| % held by institutions 1 | 89.25% |
| Shares short (28 Mar 2024) 4 | 1.42M |
| Short ratio (28 Mar 2024) 4 | 3.19 |
| Short % of float (28 Mar 2024) 4 | 1.54% |
| Short % of shares outstanding (28 Mar 2024) 4 | 1.30% |
| Shares short (prior month 29 Feb 2024) 4 | 1.36M |
Dividends & splits
| Forward annual dividend rate 4 | N/A |
| Forward annual dividend yield 4 | N/A |
| Trailing annual dividend rate 3 | 0.00 |
| Trailing annual dividend yield 3 | 0.00% |
| 5-year average dividend yield 4 | N/A |
| Payout ratio 4 | 0.00% |
| Dividend date 3 | N/A |
| Ex-dividend date 4 | N/A |
| Last split factor 2 | N/A |
| Last split date 3 | N/A |
Financial highlights
Fiscal year
| Fiscal year ends | 31 Dec 2023 |
| Most-recent quarter (mrq) | 31 Dec 2023 |
Profitability
| Profit margin | 30.14% |
| Operating margin (ttm) | 29.20% |
Management effectiveness
| Return on assets (ttm) | 8.49% |
| Return on equity (ttm) | 16.26% |
Income statement
| Revenue (ttm) | 13.12B |
| Revenue per share (ttm) | 122.93 |
| Quarterly revenue growth (yoy) | 0.60% |
| Gross profit (ttm) | N/A |
| EBITDA | 4.65B |
| Net income avi to common (ttm) | 3.95B |
| Diluted EPS (ttm) | 34.77 |
| Quarterly earnings growth (yoy) | -3.10% |
Balance sheet
| Total cash (mrq) | 10.84B |
| Total cash per share (mrq) | 100.92 |
| Total debt (mrq) | 2.79B |
| Total debt/equity (mrq) | 10.74% |
| Current ratio (mrq) | 5.69 |
| Book value per share (mrq) | 242.47 |
Cash flow statement
| Operating cash flow (ttm) | 4.59B |
| Levered free cash flow (ttm) | 2.76B |
© 2024 Yahoo. All rights reserved.